Chen R A, Tu Y, Cao Y, Liu L, Liang Y
Department of Haematology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
J Int Med Res. 2011;39(5):1975-84. doi: 10.1177/147323001103900544.
This randomized, retrospective study evaluated the effect of thalidomide combined with bortezomib-dexamethasone (TBD) or vincristine-doxorubicin-dexamethasone (T-VAD) on 46 patients with multiple myeloma. Newly diagnosed patients were randomly allocated to receive TBD (n = 24) or T-VAD (n = 22). The high-quality response rate (complete response plus very good partial response) was 62.5% in the TBD group and 45.4% for T-VAD. The complete response rate was 29.2% for TBD and 13.6% for T-VAD. Overall survival at 2 and 3 years, respectively, was 91.7% and 62.5% for TBD versus 86.4% and 54.5% for T-VAD. Most of the toxic effects of treatment were well tolerated. Both regimens were effective in the treatment of newly diagnosed multiple myeloma patients. Further studies are required to determine the role of thalidomide in these two regimens.
这项随机回顾性研究评估了沙利度胺联合硼替佐米-地塞米松（TBD）或长春新碱-阿霉素-地塞米松（T-VAD）对46例多发性骨髓瘤患者的疗效。新诊断的患者被随机分配接受TBD（n = 24）或T-VAD（n = 22）治疗。TBD组的高质量缓解率（完全缓解加非常好的部分缓解）为62.5%，T-VAD组为45.4%。TBD组的完全缓解率为29.2%，T-VAD组为13.6%。TBD组2年和3年的总生存率分别为91.7%和62.5%，而T-VAD组分别为86.4%和54.5%。治疗的大多数毒性作用耐受性良好。两种方案对新诊断的多发性骨髓瘤患者均有效。需要进一步研究以确定沙利度胺在这两种方案中的作用。
